Photo: Lightfield Studios

Okanagan Clinical Trials is pleased to announce the availability of new opportunities to participate in important clinical research trials testing key biomarkers for Alzheimer’s disease.

These studies include testing two biomarkers – APOE (Apolipoprotein E) and p-tau (phosphorylated tau protein) – that are critical to advancing the understanding and treatment of Alzheimer’s disease.

Alzheimer’s disease is the most common form of dementia and affects almost 50 million people worldwide. It is a progressive condition with no cure. Usually, it begins to affect an individual’s short-term memory, but worsens over time and eventually leads to death. Alzheimer’s most often affects people over the age of 65, but some develop young-onset dementia in their 40s and 50s.

“We are excited to offer such important research opportunities to individuals who want to make a difference in the future of Alzheimer’s research,” said Okanagan Clinical Trials President Dr. Kim Christie. “By studying biomarkers such as APOE and p-tau, we not only advance our understanding of the disease, but also pave the way for earlier diagnostic possibilities and better treatments.”

Eligibility to participate may vary depending on the specific study. In general, studies seek volunteers who meet the following criteria:

• adults aged 55-80 years
• people with a family history of Alzheimer’s disease or dementia
• people without cognitive impairment, mild cognitive impairment or early stage Alzheimer’s disease
• healthy participants

“We know that clinical research is the way to fight Alzheimer’s disease,” said Dr. Christie. “We urgently need people to participate in studies and help change the future of medicine for generations to come.”

The treatment will not affect provincial medical coverage, and all study-related costs will be paid by the sponsor. Participants are free to leave the study at any time.

To learn more about the study or to volunteer, visit www.okanaganclinicaltrials.com or call Okanagan Clinical Trials at 250-862-8141.

This article was written by or on behalf of the sponsoring client and does not necessarily reflect the views of Castanet.